)
Improvement with DUPIXENT in nasal congestion vs placebo was seen at first assessment at Week 4,a with significant results at Week 24 and Week 521,2
Post hoc analysis at Week 4 was not multiplicity controlled. Results are descriptive. Definitive conclusions cannot be made.2
aReduction in NC score in the DUPIXENT group was observed as early as the first assessment at Week 4, NC score reduction of 0.53 from a baseline score of 1.86 with DUPIXENT (n=33) vs reduction of 0.13 from a baseline score of 2.05 with placebo (n=29); LSM difference vs placebo: -0.40 (95% CI: -0.63, -0.18).2
bAt Week 24 (secondary endpoint), NC score reduction of 1.30 from a baseline score of 1.86 with DUPIXENT (n=33) vs reduction of 0.43 from a baseline score of 2.05 with placebo (n=29); LSM difference between DUPIXENT and placebo: -0.87 (95% CI: -1.18, -0.56) (P<0.0001).1,2
cAt Week 52 (secondary endpoint), NC score reduction of 1.57 from a baseline score of 1.86 with DUPIXENT (n=33) vs reduction of 0.17 from a baseline score of 2.05 with placebo (n=29); LSM difference between DUPIXENT and placebo: -1.40 (95% CI: -1.77, -1.02) (P<0.0001).1,2
Nasal congestion (NC) score: Patients rate nasal congestion symptom severity daily on a scale of 0 (no symptoms) to 3 (severe symptoms). NC score is the monthly average, with a maximum of 3. Lower score indicates improvement (less congestion).1,2
LSM, least squares mean.